HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

WIN 33377

structure in first source

Also Known As:

N-(((1-(2-(diethylamino)ethyl)amino)-9-oxo-9H-thioxanthen-4-yl)methyl)methanesulfonamide; SR 233377; SR233377; WIN 033377; WIN-033377; WIN-33377

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - WIN 33377: 4
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - WIN 33377: 4
  - Thioxanthenes: 11
    - WIN 33377: 4
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Xanthenes: 65
      - Thioxanthenes: 11
        WIN 33377: 4

Experts

1.	Boerner, Scott: 1 article (08/2008)
2.	Goncalves, Priscila H: 1 article (08/2008)
3.	High, Francine: 1 article (08/2008)
4.	Juniewicz, Paul: 1 article (08/2008)
5.	Li, Jing: 1 article (08/2008)
6.	LoRusso, Patricia M: 1 article (08/2008)
7.	Shackleton, Gareth: 1 article (08/2008)
8.	Cao, Ling-Yan: 1 article (12/2003)
9.	Huang, He: 1 article (12/2003)
10.	Ni, Jiang-Hong: 1 article (12/2003)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 12/01/2003 - "This article reviews the mechanism and efficacy of such prostate cancer drugs as bicalutamide, medroxyprogesterone acetate, megestrol acetate, flutamide and so on, as well as the clinical data and clinical uses of calcitriol analogue EB1089, SR233377, etc."
2.	Neoplasms (Cancer) 08/01/2000 - "SR233377 is a novel thioxanthenone analogue that demonstrated solid tumor selectivity in vitro with activity confirmed in vivo against several murine tumors including those of colon, pancreas, and mammary origin. " 01/01/1999 - "We conclude that SR233377 administered on a 5-day schedule is associated with tolerable clinical symptoms and some activity against a range of solid tumors but dosing is limited by QTc prolongation, a condition that predisposes to ventricular arrhythmias. " 01/01/1999 - "A group of 25 patients with a range of solid tumor diagnoses and good performance status received SR233377 at eight dose levels ranging from 4.8 mg/m2 per day to 74.7 mg/m2 per day. " 01/01/1999 - "SR233377 (WIN33377) is a novel 4-aminomethyl thioxanthone derivative with promising preclinical activity against solid tumors at doses substantially below the MTD. "
3.	Cardiotoxicity 08/01/2008 - "Due to cardiac toxicity occurring with both the parent compound, SR233377, as well as this analog, this series of agents was abandoned from further clinical development."
4.	Neutropenia 01/01/1999 - "Toxicities of SR233377 on this schedule included neutropenia, fever, nausea, and dyspnea but all were mild and not dose-limiting. "
5.	Nausea 01/01/1999 - "Toxicities of SR233377 on this schedule included neutropenia, fever, nausea, and dyspnea but all were mild and not dose-limiting. "

Related Drugs and Biologics

1.	Megestrol Acetate (Borea)
2.	Medroxyprogesterone Acetate (Depo-Provera)
3.	Flutamide (Eulexin)
4.	Calcitriol (Calcijex)
5.	seocalcitol
6.	bicalutamide (Casodex)
7.	thioxanthone